These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 10146887)
1. Cost effectiveness of surfactant replacement in preterm babies. Mugford M; Howard S Pharmacoeconomics; 1993 May; 3(5):362-73. PubMed ID: 10146887 [TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of prevention and treatment of neonatal respiratory distress (RDS) with exogenous surfactant: what has changed in the last three decades? Mugford M Early Hum Dev; 2006 Feb; 82(2):105-15. PubMed ID: 16457971 [TBL] [Abstract][Full Text] [Related]
3. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. Tubman TR; Halliday HL; Normand C BMJ; 1990 Oct; 301(6756):842-5. PubMed ID: 2126475 [TBL] [Abstract][Full Text] [Related]
4. Cost implications of different approaches to the prevention of respiratory distress syndrome. Mugford M; Piercy J; Chalmers I Arch Dis Child; 1991 Jul; 66(7 Spec No):757-64. PubMed ID: 1863120 [TBL] [Abstract][Full Text] [Related]
7. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group. Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614 [TBL] [Abstract][Full Text] [Related]
8. Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation. Egberts J Biol Neonate; 1992; 61 Suppl 1():59-65. PubMed ID: 1391268 [TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of respiratory distress syndrome in premature infants using intratracheally administered surfactants]. de Winter JP; Egberts J; de Kleine MJ; van Bel F; Wijnands JB; Guit GL Ned Tijdschr Geneeskd; 1992 Oct; 136(41):2018-24. PubMed ID: 1407193 [TBL] [Abstract][Full Text] [Related]
10. Surfactant replacement therapy--economic impact. Pejaver RK; al Hifzi I; Aldussari S Indian J Pediatr; 2001 Jun; 68(6):501-5. PubMed ID: 11450378 [TBL] [Abstract][Full Text] [Related]
11. Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits. Mihaylova A; Kristina K; Kasnakova P; Gueorguiev S; Gueorguieva P; Bakova D; Parahuleva N Afr Health Sci; 2024 Mar; 24(1):220-227. PubMed ID: 38962356 [TBL] [Abstract][Full Text] [Related]
12. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Kattwinkel J; Bloom BT; Delmore P; Davis CL; Farrell E; Friss H; Jung AL; King K; Mueller D Pediatrics; 1993 Jul; 92(1):90-8. PubMed ID: 8516091 [TBL] [Abstract][Full Text] [Related]
14. Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant ('Curosurf'). Egberts J Pharmacoeconomics; 1995 Oct; 8(4):324-42. PubMed ID: 10155674 [TBL] [Abstract][Full Text] [Related]
15. Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant. Lancet; 1992 Dec; 340(8832):1363-9. PubMed ID: 1360087 [TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population. Salinas-Escudero G; Reyes-López A; Garduño-Espinosa J; Villasís-Keever MA; Martínez-Valverde S; Muñoz-Hernández O Salud Publica Mex; 2012; 54 Suppl 1():S73-81. PubMed ID: 22965446 [TBL] [Abstract][Full Text] [Related]